Slynd

Quick links to important sections

Slynd

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Slynd

Property Description
Active ingredient Drospirenone (DRSP)
Form Film-coated oral tablets (24 active + 4 inert)
Pharmacological class Progestin-Only Oral Contraceptive (POP)
Common use Pregnancy prevention
Manufacturer Exeltis USA INC (US) / Duchesnay Inc. (Canada)
Status Prescription-only medication (Rx)

Defining Slynd: Type and Primary Purpose

Slynd is a prescription-only medication classified as an oral contraceptive that is indicated for pregnancy prevention in females of reproductive potential. It belongs to the pharmacological class of progestins, which are synthetic compounds designed to mimic the activity of the natural hormone progesterone. This medicine is distinguished by its composition as a newer generation, single-ingredient oral contraceptive, often used in scenarios where estrogen-containing therapies are medically inappropriate or contraindicated.

Composition: The Estrogen-Free Formulation

The preparation's sole active ingredient is Drospirenone (DRSP), making it a definitive progestin-only pill (POP) that is completely estrogen-free. Drospirenone is a synthetic steroid categorized as a fourth-generation progestin. This product is manufactured by Exeltis USA INC in the United States, and the formulation is presented as twenty-four active white tablets followed by four inert green tablets, known as a 24/4 dosing regimen.

Drospirenone's Unique Activity

Drospirenone possesses a distinct pharmacological profile among progestins, primarily because it exhibits both antiandrogenic activity and mild anti-mineralocorticoid activity. The compound is chemically related to spironolactone, which contributes to its mild anti-mineralocorticoid property, allowing it to act as an aldosterone antagonist. Pharmacological studies support that this differentiation is a key feature setting Drospirenone apart from older progestin formulations.

What side effects are possible with Slynd?

The official safety profile for Slynd is established by government regulatory documents, detailing classified adverse reactions and specific safety constraints.

Frequency-Classified Adverse Reactions

The most common adverse reactions (those occurring in more than 1% of users) documented in official labeling typically include those affecting the reproductive system and breast disorders, such as metrorrhagia (heavy bleeding), irregular menstruation, dysmenorrhea (painful periods), vaginal hemorrhage, breast pain, and breast tenderness. Other common effects involve the nervous system (headache), gastrointestinal system (nausea), and skin (acne), along with reported weight increased and libido decreased. Bleeding irregularities and spotting are classified as Very Common (ge 10%), especially during the first three months of use, and generally tend to decrease over time.

Serious Adverse Reactions and Restrictions

The prescribing information notes the risk of serious adverse reactions, which include Hyperkalemia (high blood potassium) due to drospirenone’s anti-mineralocorticoid activity. This risk leads to mandatory contraindications in females with renal impairment or adrenal insufficiency. Other serious documented risks are Arterial or Venous Thromboembolic Events (blood clots), Ectopic Pregnancy, Liver Tumors (benign or malignant), and concerns related to Bone Loss and Cervical Cancer.

Population-Specific Safety Notes

The medicine is contraindicated in females with hepatic impairment and undiagnosed abnormal uterine bleeding. For females taking certain medications that may increase potassium levels, official labeling specifies that monitoring of serum potassium concentration is advised before and during the first treatment cycle. The medicine is not indicated for use in geriatric women.

Overdose and Emergency Response

The official regulatory profile for Slynd overdose describes manifestations consistent with high exposure to progestin-only contraceptives. Documented overdose presentations may include symptoms such as nausea, vomiting, and withdrawal bleeding in females, which are generally categorized as non-serious. There have been no reports of serious deleterious effects resulting directly from a high exposure event.

Despite the mild presentations, the primary regulatory concern in the event of an overdose relates to the anti-mineralocorticoid activity of drospirenone, which creates the potential for severe electrolyte disturbances. The official labeling mandates the monitoring of physiological changes: specifically, elevated serum potassium (hyperkalemia), disturbances in serum sodium (hyponatremia), and evidence of metabolic acidosis.

Immediate medical help must be sought if any signs of severe electrolyte imbalance appear, particularly in patients with predisposing conditions like renal impairment or adrenal insufficiency, who are noted in the label as being at increased risk for hyperkalemia. Treatment is defined as symptomatic and supportive, and official regulatory documents confirm that no specific antidote is known for drospirenone overdose. The need for urgent help is therefore tied specifically to these severe, documented physiological outcomes.

Therapeutic Uses of Slynd

What Slynd Treats: Main Uses and Benefits

The primary therapeutic domain of Slynd is fertility regulation, being commonly used for pregnancy prevention in females of reproductive potential. It is considered relevant as an estrogen-free option for patients who may benefit from this type of hormonal method due to specific medical considerations. This use supports the patient during difficult episodes by easing distress where estrogen-related risks must be actively mitigated.

The medication is also applied across domains where additional symptomatic support is needed. It helps manage groups of symptoms that appear suddenly or fluctuate, including acne and hirsutism (abnormal hair growth), symptoms of fluid retention like bloating, and dysmenorrhea (painful cramping). This usage may assist with easing the overall symptom load related to androgenic effects and contributes to supportive relief during episodes of discomfort.

Quick Fact: Supportive Management for Fluid-Related Discomfort

Regulatory References

  1. National Institutes of Health (NIH) - Clinical Review

Eligibility and Restrictions for Use

Slynd is officially indicated for use by females of reproductive potential to prevent pregnancy. Eligibility to use the medicine is strictly defined by regulatory authorities based on organ function, hormone-sensitive conditions, and age.

Contraindicated Conditions
Renal impairment or kidney failure
Adrenal insufficiency
Liver tumors (benign or malignant) or hepatic impairment
Presence or history of cervical cancer or progestin-sensitive cancers
Undiagnosed abnormal uterine bleeding

Use is also prohibited immediately if pregnancy occurs or if a thromboembolic event develops. Due to the anti-mineralocorticoid activity of drospirenone, patients with conditions that predispose to hyperkalemia require monitoring of serum potassium concentration before and during the initial treatment cycle.

Age-related constraints establish that use is not indicated before the onset of menstruation (menarche) and is not indicated for postmenopausal (geriatric) women. While the medicine is to be discontinued in pregnancy, official documents state that use is permitted during lactation (breastfeeding), as negligible amounts of drospirenone are expected to be transferred to the infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Slynd (drospirenone) documents two primary interaction domains: effects on drug exposure via metabolism and pharmacodynamic effects on serum potassium.

Pharmacokinetic Interactions

Drospirenone's metabolism is influenced by the CYP3A4 enzyme system, leading to interactions that may alter its systemic exposure and contraceptive efficacy.

Interaction Type Interacting Agents (Examples) Resulting Constraint or Requirement
Reduced Exposure CYP3A4 Inducers (e.g., Carbamazepine, Phenytoin, St. John's Wort) Alternative or back-up non-hormonal contraception is required during co-administration and for 28 days following discontinuation.
Increased Exposure Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Indinavir, Clarithromycin) Increased drospirenone plasma levels are expected; monitoring of serum potassium is considered for long-term use.

Pharmacodynamic Interactions

Due to drospirenone's anti-mineralocorticoid activity, co-administration with other substances that elevate potassium levels increases the risk of hyperkalemia.

Interaction Domain Interacting Agents (Categories) Primary Concern
Potassium Elevation ACE Inhibitors, ARBs, Potassium-Sparing Diuretics, Potassium Supplements, NSAIDs, Heparin Increased risk of hyperkalemia.

Regulatory agencies also note that the entire hyperkalemia risk class of interactions is heightened in populations where Slynd is contraindicated, such as those with Renal Impairment, Adrenal Insufficiency, or Hepatic Impairment.

Mechanism of Action

Drospirenone, the active progestin in Slynd, functions as a high-affinity agonist of the progesterone receptor (PR), primarily within the hypothalamic-pituitary-ovarian axis. PR activation in the pituitary gland results in the suppression of gonadotropin secretion, specifically luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This upstream signal modification culminates in the inhibition of follicular development and the subsequent prevention of ovulation, which is the principal system-level physiological consequence.

Downstream of this primary action, PR agonism alters the cervical mucus consistency, rendering it thicker and less permeable to sperm transit. Furthermore, drospirenone modifies the endometrium, inducing cellular and structural changes that decrease its receptivity.

Drospirenone exhibits additional pharmacodynamic activity as a non-selective antagonist of the mineralocorticoid receptor (MR). This interaction modulates the actions of aldosterone, leading to altered renal tubule handling of ions and water, resulting in increased sodium and water excretion and potassium retention.

Dosage and Administration Information

How to Use Slynd: Official Administration Guidelines

Slynd is an oral contraceptive pill taken daily for 28 consecutive days. It is essential to swallow the tablets whole and take them at approximately the same time each day to ensure the interval between doses is exactly 24 hours.

Dosing Protocol

The blister pack contains 28 tablets, which must be taken in the order indicated:

  • Active Tablets (Days 1–24): One white active tablet is taken daily for the first 24 days.
  • Inactive Tablets (Days 25–28): One green inert tablet is taken daily for the final 4 days.

A new pack must be started immediately after the last inactive tablet, without any break in daily pill intake.

Starting the First Pack

For those not currently using hormonal contraception, the first white active tablet should be taken on the first day of the natural menstrual period (Day 1 Start). When switching from another contraceptive method (such as a combined pill, patch, or ring), the first Slynd tablet should preferably be started the day after the last active tablet of the previous method.

Missed Dose Instructions

Type of Tablet Missed Action to Take Back-up Contraception (for 7 days)
One active (white) tablet Take the missed tablet as soon as possible and continue with the rest of the pack as usual. Not necessary.
Two or more active (white) tablets Take the last missed tablet as soon as possible and continue with the rest of the pack as usual (discarding any earlier missed pills). Necessary if sex occurs within 7 days after the missed pills.
One or more inert (green) tablets Skip the missed inert tablet(s) and continue taking the remaining pills until the pack is finished. Not necessary.

If vomiting or diarrhea occurs within 3–4 hours of taking an active tablet, a new tablet (the one scheduled for the next day) should be taken as soon as possible, ideally within 12 hours of the usual time.

Recent Clinical Evidence

Slynd: Recent Clinical Evidence

Efficacy in Contraception

Clinical development programs, including three Phase 3 trials (Studies 301, 302, and 303), examined the agent's effectiveness in preventing pregnancy in adult females of reproductive age. In a pooled analysis of the two European studies (301 and 302), the overall Pearl Index (PI) was calculated as 0.73 pregnancies per 100 person-years. The U.S. study (303) reported an overall PI of 2.4 per 100 person-years.

Tolerability and Adverse Events

The safety and tolerability of the drospirenone progestin-only pill were assessed in all completed trials. The proportion of patients who discontinued the studies due to bleeding irregularities ranged from 3.3% to 6.0% across the trials.

Reported adverse events observed in the trials most commonly included acne, headache, metrorrhagia (bleeding between periods), and breast pain.

Bleeding Pattern Observation Percentage of Patients Study Context
Experiencing unscheduled bleeding/spotting 52% to 65% (in last follow-up period) Common for progestin-only pills
Discontinued due to bleeding irregularities 3.3% to 6.0% (across all trials)

Specialized Safety Monitoring

Due to drospirenone's anti-mineralocorticoid activity, the potential for hyperkalemia (elevated potassium levels) was a safety issue of special interest. Most patients who had elevated serum potassium levels during the clinical studies had mild or isolated increases that returned to normal while continuing the study medication. Trial participants were monitored for this event, and individuals with pre-existing conditions like severe renal, hepatic, or adrenal impairment were excluded from the studies.

Frequently Asked Questions (FAQ)

Common questions about Slynd (FAQ)


Q: How quickly does Slynd start preventing pregnancy?

According to the official product information, if Slynd initiation occurs on the first day of the menstrual period, no additional contraceptive measures are indicated when starting on Day 1. If starting later, barrier contraception is recommended for the first seven days.


Q: Do you have to take Slynd at the exact same time every day, like other mini-pills?

Official guidance suggests taking tablets at approximately the same time each day to ensure the 24-hour interval between doses. Slynd's active pills have a 24-hour missed pill window, meaning if an active pill is taken less than 24 hours late, back-up contraception is not required.


Q: What happens if I forget to take a Slynd pill?

If an active tablet is missed by less than 24 hours, the recommendation is to take it right away and continue the pack as usual. If an active tablet is missed by more than 24 hours, the official recommendation is to take the last missed pill immediately and use a barrier method for the next seven days, as detailed in the prescribing information.


Q: Is it common to have irregular bleeding or spotting when starting Slynd?

Studies and official information indicate that irregular bleeding and spotting are very common adverse events, especially during the first three months of taking Slynd. This pattern is generally common with progestin-only pills and may decrease over time as the body adjusts to the medication.


Q: Can I switch directly from a combination pill to Slynd?

Official guidelines state that when switching from a combined hormonal contraceptive, Slynd should be started the day after the last active tablet or dose of the previous method. Starting at this time is generally advised, and typically no additional contraceptive measures are indicated.


Q: Are stomach upset or nausea common when first starting Slynd?

Official product information notes that nausea is a common side effect of Slynd. This effect is generally more likely to occur during the first few months of treatment as the body adjusts to the medication.


Q: Are there any herbal supplements that should be avoided while on Slynd?

Regulatory documents explicitly identify St. John's Wort as an herbal supplement that can reduce the effectiveness of Slynd. If St. John's Wort is used, an alternative or back-up non-hormonal method of contraception is required, as it is classified as a strong enzyme inducer.


Q: Does taking Slynd affect liver function or require monitoring?

Slynd is contraindicated (should not be used) in individuals with liver tumors or hepatic impairment. For others, while routine liver function monitoring is generally not specified in the labeling for all users, monitoring of serum potassium levels is advised for those also taking strong CYP3A4 inhibitors.


Q: What is the benefit of the placebo pills in the Slynd pack?

The final four green tablets in the pack are inert (placebo) and contain no active medicine. According to official resources, these pills are included to help maintain the daily routine of taking one pill, which helps ensure the new active pack is started on time.


Q: Does Slynd offer protection against sexually transmitted infections?

Official patient information explicitly states that Slynd is a form of birth control and does not protect against HIV infection (the cause of AIDS) or any other sexually transmitted diseases (STDs).


Q: Is Slynd often prescribed for non-contraceptive benefits?

Slynd's official indication, as stated in regulatory documents, is for pregnancy prevention in females of reproductive potential. The medicine is not indicated by the manufacturer for other health conditions.


Q: Can Slynd cause changes in breast tenderness or size?

Regulatory safety information lists breast pain and breast tenderness as common adverse reactions documented during clinical trials. Changes in the actual size of the breast are not typically highlighted in the core adverse event sections of official documentation.


Q: Are there any dietary restrictions recommended while taking Slynd?

Due to the anti-mineralocorticoid activity, there is a potential for high blood potassium (hyperkalemia). Patients are advised to discuss with a healthcare provider any necessary limits on potassium-rich foods or avoidance of grapefruit/grapefruit juice.


Q: What should I do if vomiting or diarrhea occurs after taking the pill?

Official instructions specify that if vomiting or severe diarrhea occurs within a few hours of taking an active tablet, a new active tablet should be taken from the blister pack as soon as possible, ideally within 12 hours of the usual time.


Q: Are there any known interactions between Slynd and common medications for anxiety or depression?

Official product information warns that Slynd can interact with medicines that are strong inhibitors or inducers of the CYP3A4 enzyme or that increase serum potassium levels. Patients taking medications for anxiety or depression should consult the prescribing information for those drugs to check for these specific interaction profiles.


Q: Is it normal to completely lose my period while taking Slynd?

Official patient information acknowledges that some women using hormonal contraceptives may miss periods or experience amenorrhea (absence of bleeding). If a period is missed for two or more months in a row, or missed after improper pill use, it is recommended that a healthcare provider be contacted to rule out pregnancy.

How should Slynd be stored and disposed of?

Storage and Disposal Requirements for Slynd (Drospirenone)

Official regulatory information specifies essential requirements for storing and disposing of Slynd to maintain product quality and safety.

Storage Conditions

Requirement Official Documentation Summary
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Handling Keep in the original blister card and package to protect the medicine from external factors.
Child Safety As with all medicines, Slynd must be kept strictly out of the reach of children.
Stability The product has a documented shelf-life of 3 years when stored as specified.

Disposal Instructions

Disposal of any unused medication or waste material must be performed in accordance with local pharmaceutical waste regulations. This medicinal product may pose a risk to the environment, and specific instructions, such as consulting a healthcare professional for guidance, should be followed when discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Slynd found in:

A-Z Index: